“My doctor explained there’s compelling data showing longer treatment can really benefit patients like me. We’re opting to stay with GLIVEC for up to 3 years.”
KIT+ GIST patients on adjuvant GLIVEC may start to question the need to continue therapy. They need to know:
- In a pre-GLIVEC study, resected GIST patients had a 54% survival rate at 5 years1
—Once GIST recurs, the patient is considered metastatic and the chance of cure is extremely low2
- Clinical data demonstrate that adjuvant treatment with 3 years of GLIVEC provides a significant benefit vs 1 year in both recurrence-free survival and overall survival at 5 years4
- Updated guidelines from the National Comprehensive Cancer Network® (NCCN®) and the European Society for Medical Oncology (ESMO) support the use of adjuvant GLIVEC for at least 36 months in appropriate KIT+ GIST patients2,5
Models are used for illustrative purposes only throughout the site. Patient quotes are intended for guidance only and do not reflect actual patient testimonials.
References: 1. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231(1):51-58. 2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Soft Tissue Sarcoma V.2.2016. © National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed September 21, 2016. To view the most recent and complete version of the guideline, go online to www.nccn.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc. 3. Sutent® (sunitinib malate) summary of product characteristics. Sandwich, Kent, UK: Pfizer Ltd. 4. Glivec® (imatinib) summary of product characteristics. Dublin, Ireland: Novartis Europharm Limited. 5. The ESMO/European Sarcoma Network Working Group. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(suppl 3):ii21-ii-26.